Two Directors at Sandvik AB bought/sold 572,360 shares at between 201.391SEK and 204.019SEK. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
We expect Pandora to report a solid start to the year, with 6.4% LFL growth (consensus 5.6%) in Q1e, but believe focus is more likely to be on the implications (direct and indirect) of tariffs and higher silver prices. However, we believe these concerns are more than priced in after recent share-price weakness. We reiterate our BUY, but have lowered our target price to DKK1,400 (1,550).
We forecast Q1 organic sales growth of just 0.6% YOY, below the full-year guidance, owing to persistent headwinds in wholesale. However, with Managed Care headwinds set to annualise from Q2, better quarters should lie ahead. We expect an unchanged 2025 guidance of 3–7% organic sales growth and DKK4.5bn–4.9bn in EBIT, but we find the lower end most likely. We reiterate our BUY but have cut our target price to DKK300 (320).
Despite increased uncertainty in its comments, management seems fairly upbeat, in our view, considering the macro turmoil. SMM daily order intake was stable in the first two weeks of Q2 versus Q1, and Sandvik sees a limited impact on the margin from tariffs. Mining remained solid in Q1, with a strong outlook (especially in gold and copper), while infrastructure and industrial activity remained low (weak cutting tools orders). We have lowered our 2025–2027e adj. EBITA by c4% (roughly half due to ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.